|
EP2253307A1
|
|
L-Carnitin for supression of crystallisation
|
|
EP1862163A1
|
|
L-Carnitin for supression of crystallisation
|
|
EP1762231A1
|
|
Sustained release magnesium microtablets
|
|
US2007043229A1
|
|
Process for preparing certain hydrohalide metal complex compounds having a specific coarse structure
|
|
EP1627879A1
|
|
Process for preparing hydrohalogen metal complexes of specific particle size
|
|
DE3814856A1
|
|
MEANS FOR PROPHYLAXIS OF THE HEART INFARM AND FOR PREVENTING THE REINFARK
|
|
DE3809625A1
|
|
ORAL-AVAILABLE PHARMACEUTICAL AGENT, IN PARTICULAR FOR IRON AND MAGNESIUM SUBSTITUTION THERAPY
|
|
DE3238118A1
|
|
METHOD FOR PRODUCING COMPLEX COMPOUNDS FROM AMINODICARBONIC ACIDS, DUAL VALUE METALIONS AND HALOGENIDIONS
|
|
DE2720288A1
|
|
PREPARATION FOR TREATING ANIMALS
|
|
US4137326A
|
|
Use of magnesium monospartate hydrochloride complex
|
|
DE2507354A1
|
|
PHARMACEUTICAL PREPARATION
|
|
DE2456350A1
|
|
3 - Separator for poisonous grasses and grain
|
|
DE2228101A1
|
|
PROCESS FOR THE PREPARATION OF COMPLEX COMPOUNDS OF AMINODICARBONIC ACIDS WITH MAGNESIUM AND HALOGENES
|
|
CA936541A
|
|
Magnesiummonoaspartate hydrohalogenides, a process for their manufacture and drugs which contain these compounds as active agents
|
|
GB1283810A
|
|
Magnesium aspartate hydrohalides
|
|
DE1809120A1
|
|
Magnesium monoaspartate hydroiodicle useful - in treating thyroid ailments
|
|
DE1809119A1
|
|
Magnesium aspartate prepn for the treatment - of infarction conditions
|
|
DE1809121A1
|
|
Magnesium monoaspartate hydrobromide useful - as a sectative or tranquilliser
|
|
DE1215637B
|
|
Process for increasing the sclerotinization of ergot mycelium in saprophytic culture
|
|
DE1232157B
|
|
Process for the preparation of benzilic acid tropine ester hydrochloride
|
